Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-1,3-galactosyltransferase 2 (A3GALT2) is an enzyme that catalyzes the transfer of galactose from UDP-Galactose to acceptor molecules, involved in the synthesis of isoglobotrihexosylceramide (iGb3) and related glycosphingolipids in some mammals[1][2][3]. However, in humans, the A3GALT2 gene is nonfunctional (a pseudogene), and does not produce an active enzyme, meaning humans do not synthesize iGb3 via this pathway[2][3][4]. Consequently, it is not considered an active therapeutic target or biomarker in humans, though it is studied in other species for its immunological implications, particularly in xenotransplantation research[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-1,3-galactosyltransferase 2 (A3GALT2).